Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jul 30, 2024

Over the last month, the Cosmetic industry ($JWN, $SBH, $COTY, $UG, $TUP) has witnessed a notable surge of +25.82% in its overall performance.

The Cosmetic sector has experienced a significant increase of +25.82% in its performance over the past month.
Tickers in the industry - $JWN, $SBH, $COTY$UG$TUP


Robots for this industry :
Swing Trader, Long Only: Valuation & Efficiency Model (TA&FA) 
Day Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)

 

The Cosmetic sector has showcased a remarkable upsurge of +25.82% in its performance over the past month, marking a significant positive shift in the industry. This article delves into the key themes and notable companies within this sector, shedding light on recent price movements and volume trends.

Theme and Notable Companies

The Cosmetic sector encompasses companies that produce cosmetic products ranging from makeup to personal care items like shampoos and soaps. Several of these companies also have a foothold in the pharmaceutical and healthcare domains. Noteworthy participants in this domain include Nordstrom (NYSE: JWN) and Tupperware Brands Corp (NYSE: TUP).

Market Capitalization

The average market capitalization across the cosmetic theme stands at $2.8 billion, with a diverse range of valuations within the sector. The market capitalization of tickers in this group spans from $34.7 million to $9.6 billion, with COTY holding the highest valuation at $9.6 billion, while UG is positioned at the lower end with a valuation of $34.7 million.

Price Movements and Notable News

The past period has seen a mix of price movements within the Cosmetic sector. On a weekly basis, the average price growth was -11.18%. However, over the entire month, the sector experienced a noteworthy average growth of 25.82%. Over the quarter, the sector's performance witnessed a dip with an average price growth of -25.42%. Among the companies, UG saw the highest price growth at -0.81%, while TUP encountered the most substantial fall at -25.07%.

Volume Trends

Volume trends provide valuable insights into market sentiment. The average weekly volume growth across all stocks in the cosmetic theme was -5.82%. However, the monthly volume growth demonstrated a more substantial decline at -58.88%, while the average quarterly volume growth was a positive 3.19%. These fluctuations indicate the dynamic nature of trading activity within the cosmetic sector.

Notable Stock Movements

  1. Momentum Indicator for UG turns negative, indicating new downward trend

United-Guardian, Inc. (UG) recently observed its Momentum Indicator dipping below the 0 level, potentially heralding a new downward trend. Tickeron's A.I. analysis reveals that in similar instances, stocks often continued to decline. The odds of a decline stand at 71%, with the stock already experiencing a -7% downtrend throughout the last month.

  1. Momentum Indicator for COTY turns negative, indicating new downward trend

Coty Inc. (COTY) is displaying a similar negative trend, as its Momentum Indicator moved below 0, signaling the potential for a new downward movement. Tickeron's analysis suggests that in similar circumstances, stocks have often gone on to decline further. The odds of a decline are estimated at 80%, with COTY already having undergone an -11% downtrend during the past month.

  1. SBH in downward trend: 10-day moving average broke below 50-day moving average on August 04, 2023

Sally Beauty Holdings Inc. (SBH) saw its 10-day moving average cross below the 50-day moving average, indicative of a shift in trend toward a downward trajectory. While this pattern has historically led to upward movement, in this case, the odds of a continued downward trend are estimated at 86%. SBH has already experienced a significant -20% downtrend during the last month.

Summary

The Cosmetic sector's recent performance, with a notable 25.82% monthly growth, has attracted attention. Notable companies like Nordstrom and Tupperware Brands Corp are active players in this dynamic sector. While some stocks are showing negative momentum indicators, indicating a potential downward trend, the dynamic nature of this industry suggests the need for careful observation of market trends.


Contributor

Dem Sem's AvatarDem Sem|Expert

Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.